Cited by 59Sexual function and dysfunction studiesCancer survivorship and careWomen's cancer prevention and management

Management of sexual dysfunction in breast cancer survivors: a systematic review

Open access
Seav, Susan M., Dominick, Sally A., Stepanyuk, Boris, Gorman, Jessica R., Chingos, Diana T., Ehren, Jennifer L., Krychman, Michael L., Su, H. Irene·2015·Women s Midlife Health

Abstract

Female sexual dysfunction occurs frequently in midlife breast cancer survivors (BCS) and encompasses problems with sexual desire, interest, arousal, orgasm and genitopelvic pain. Although common, sexual problems are under-diagnosed and under-treated in BCS. The objective of this review was to assess primary studies that intervene on sexual dysfunction in BCS. In February 2015, PubMed, SCOPUS, CINAHL, COCHRANE and Web of Science databases were systematically searched for randomized controlled clinical trials (RCTs) of vaginal (lubricants, moisturizers, estrogens, dehydroepiandrosterone [DHEA], testosterone, vibrators, dilators), systemic (androgens, anti-depressants, flibanserin, ospemifene), physical therapy (physical activity, pelvic floor training), counseling and educational interventions on sexual function in BCS. Observational studies of vaginal interventions were also included due to the paucity of RCTs. The search yielded 1414 studies, 34 of which met inclusion criteria. Both interventions and outcomes, measured by 31 different sexual function scales, were heterogeneous, and therefore data were not pooled. The review found that regular and prolonged use of vaginal moisturizers was effective in improving vaginal dryness, dyspareunia, and sexual satisfaction. Educational and counseling interventions targeting sexual dysfunction showed consistent improvement in various aspects of sexual health. No consistent improvements in sexual health were observed with physical activity, transdermal testosterone or hot flash interventions. There was a lack of BCS-specific data on vaginal lubricants, vibrators, dilators, pelvic floor therapy, flibanserin or ospemifene. Overall, the quality of evidence for these studies was moderate to very low. Because each of the interventions with BCS data had limited efficacy, clinical trials to test novel interventions are needed to provide evidence-based clinical recommendations and improve sexual function in BCS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40695-015-0009-4

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [94]Bachmann GA, Notelovitz M, Gonzalez SJ, Thompson C, Morecraft BA. Vaginal dryness in menopausal women: clinical characteristics and nonhormonal treatment. Clinical Practice Sexuaity. 1991;7(9):1–8.

Cited by

Sorted by citations

Authors
Seav, S. M., Dominick, S. A., Stepanyuk, B., Gorman, J. R., Chingos, D. T., Ehren, J. L., Krychman, M. L., & Su, H. I.
Affiliations
  • University of California San Diego (US)
  • Young Survival Coalition (US)
  • University of California, Irvine (US)
Venue
Women s Midlife Health
Published
2015-11-02
Volume
1
Issue
1
Pages
9-9
ISSN
2054-2690 (ISSN-L)
OpenAlex
W2199258687
Cited by
59
References
104
Citations by year
2026: 8 · 2025: 6 · 2024: 6 · 2023: 12 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 2 · 2017: 1 · 2016: 1
FWCI
0.18
Type
journal article
Language
en
Open access
Locations
  • Women s Midlife Health (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Breast Cancer Research Program (120500-PFT-11-008-01-CPPB, HD-058799-01)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
female sexual dysfunction, breast cancer survivors, vaginal dryness, dyspareunia, sexual desire, sexual arousal, orgasm, vaginal moisturizers, vaginal lubricants, flibanserin, ospemifene, testosterone, pelvic floor physiotherapy, counseling intervention, sexual health, middle-aged women

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review